The BeNeLuxA initiative is set to take on Zolgensma (onasemnogene abeparvovec), an innovative gene therapy for children under two years old with spinal muscular atrophy (SMA), which was granted conditional approval for use in Europe in May. Belgium, Ireland, and the Netherlands will undertake a joint health technology assessment (HTA) of Zolgensma as part of the application from AveXis, a Novartis company, with Austria serving as expert reviewer. The participating national HTA bodies are committed to aligning their timelines, methodology, and content of HTA processes, and after assessment, the countries will determine if they will enter joint price negotiations. However, whether Zolgensma will be reimbursed is up to the discretion […]
Good decisions start with the most accurate data
NAVLIN Price & Access Data (formerly Pricentric ONE by EVERSANA™) is part of the NAVLIN ecosystem of data, software and insights solutions.
NAVLIN Price & Access Data is the industry’s most comprehensive, highly accurate database of global price and market access intelligence, providing the right answers to the right questions to inform your strategy at launch and beyond.
Follow our showcase page on LinkedIn!